Cost-Effectiveness of Tirzepatide Versus Liraglutide, Both Adjunct to Diet and Exercise, for Patients with Obesity or Overweight: A UK Perspective
On the basis of this simulation model, at the UK willingness-to-pay threshold (£20,000/QALY gained), tirzepatide is a cost-effective treatment compared to liraglutide for overweight and obesity, in both the full license SURMOUNT-1 trial population and in liraglutide's specific NICE reimbursed population.
Authors
- Erin Johansson (ORCID: https://orcid.org/0009-0006-3178-1622)
- N. van Hest
- Matthew Capehorn (ORCID: https://orcid.org/0000-0002-8196-2505)
- Keith Tolley (ORCID: https://orcid.org/0000-0001-9732-2994)
- J. G. Evans (ORCID: https://orcid.org/0000-0003-4194-1416)
- G Cotterill
- Alun Davies
- F Godbeer
Institutions
- Eli Lilly (United States) (US)
- The Rotherham NHS Foundation Trust (GB)
- Costello Medical Consulting (United Kingdom) (GB)
Publication Details
- Journal
- Advances in Therapy
- Published
- 2025-08-11
- DOI
- https://doi.org/10.1007/s12325-025-03288-3
- Primary Topic
- Pharmacology and Obesity Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Eli Lilly and Company